Abstract
| Original language | English |
|---|---|
| Article number | 162 |
| Journal | BMC Neurology |
| Volume | 18 |
| DOIs | |
| Publication status | Published - 3 Oct 2018 |
Fingerprint
Keywords
- multiple sclerosis
- clinically isolated syndrome
- beta-interferon
- glatiramer acetate
- systematic review
- economic evaluation
Cite this
Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis : systematic review and network meta-analysis of trials including recommended dosages. / Melendez-Torres, G. J. (Corresponding Author); Armoiry, Xavier; Court, Rachel; Patterson, Jacoby; Kan, Alan; Auguste, Peter; Madan, Jason; Counsell, Carl; Ciccarelli, Olga; Clarke, Aileen.
In: BMC Neurology, Vol. 18, 162, 03.10.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis
T2 - systematic review and network meta-analysis of trials including recommended dosages
AU - Melendez-Torres, G. J.
AU - Armoiry, Xavier
AU - Court, Rachel
AU - Patterson, Jacoby
AU - Kan, Alan
AU - Auguste, Peter
AU - Madan, Jason
AU - Counsell, Carl
AU - Ciccarelli, Olga
AU - Clarke, Aileen
N1 - This work is part of a larger report commissioned by the NIHR HTA Programme as project number ID809. Aileen Clarke and G.J. Melendez-Torres are partly supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care West Midlands at the University Hospitals Birmingham NHS Foundation Trust. The views expressed are those of the authors and not necessarily those of the NHS, NIHR, NICE or the Department of Health and Social Care.
PY - 2018/10/3
Y1 - 2018/10/3
N2 - We systematically reviewed the comparative effectiveness of injectable beta-interferons (IFN-β) and glatiramer acetate (GA) on annualised relapse rate (ARR), progression and discontinuation due to adverse events (AEs) in RRMS, using evidence from within the drugs’ recommended dosages.
AB - We systematically reviewed the comparative effectiveness of injectable beta-interferons (IFN-β) and glatiramer acetate (GA) on annualised relapse rate (ARR), progression and discontinuation due to adverse events (AEs) in RRMS, using evidence from within the drugs’ recommended dosages.
KW - multiple sclerosis
KW - clinically isolated syndrome
KW - beta-interferon
KW - glatiramer acetate
KW - systematic review
KW - economic evaluation
U2 - 10.1186/s12883-018-1162-9
DO - 10.1186/s12883-018-1162-9
M3 - Article
VL - 18
JO - BMC Neurology
JF - BMC Neurology
SN - 1471-2377
M1 - 162
ER -